nemtabrutinib + efavirenz

**Nemtabrutinib + efavirenz** is a combination of two oral small molecule drugs: nemtabrutinib, a reversible inhibitor of Bruton’s tyrosine kinase (BTK), primarily under investigation for treating B-cell malignancies, and efavirenz, an approved non-nucleoside reverse transcriptase inhibitor (NNRTI) used widely as part of antiretroviral therapy for HIV-1 infection. Nemtabrutinib inhibits BTK to suppress malignant B-cell activation and survival, while efavirenz blocks HIV reverse transcriptase, preventing viral replication. Although their co-administration has been investigated for potential drug-drug interactions due to overlapping oral administration routes and hepatic metabolism (not as a therapeutic fixed combination), there is no clinical evidence supporting this specific combination as a dual-ingredient marketed or investigational therapy[1][2][4][6].

Brand names

StocrinAtripla

Other names

nemtabrutinibefavirenz